Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Constantinos ZamboglouDimos Baltas

Abstract

To demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal tissue complication probability (NTCP) of IMRT dose painting using 68Ga-HBED-CC PSMA PET/CT for target delineation in prostate cancer (PCa). 10 patients had PSMA PET/CT scans prior to prostatectomy. GTV-PET was generated on the basis of an intraprostatic SUVmax of 30%. Two IMRT plans were generated for each patient: Plan77 which consisted of whole-prostate IMRT to 77Gy, and Plan95 which consisted of whole-prostate IMRT to 77Gy and a simultaneous integrated boost to the GTV-PET up to 95Gy (35 fractions). The feasibility of these plans was judged by their ability to adhere to the FLAME trial protocol. TCP-histo/-PET were calculated on co-registered histology (GTV-histo) and GTV-PET, respectively. NTCPs for rectum and bladder were calculated. All plans reached prescription doses whilst adhering to dose constraints. In Plan77 and Plan95 mean doses in GTV-histo were 75.8±0.3Gy and 96.9±1Gy, respectively. Average TCP-histo values for Plan77 and Plan95 were 70% (range: 15-97%), and 96% (range: 78-100%, p<0.0001). Average TCP-PET values for Plan77 and Plan95 were 55% (range: 27-82%), and 100% (range: 99-100%, p<0.0001). There was no significa...Continue Reading

Citations

Jun 6, 2018·The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica·Bettina Beuthien-Baumann, Stefan A Koerber
Aug 6, 2019·Seminars in Oncology·Rosa FontiSilvana Del Vecchio
Jan 6, 2018·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Jeremie CalaisNicholas G Nickols
Nov 1, 2020·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Dejan KostyszynConstantinos Zamboglou
Jul 15, 2021·Nuklearmedizin. Nuclear Medicine·Constantin LapaUNKNOWN “Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN”
Jul 15, 2021·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Constantin LapaUNKNOWN Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.